Lupin Stock - Weekly review and sector comparison
19.06.2026 - 18:15:03 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 18:11 IST. Details in the imprint.
Lupin (INE326A01037) remains one of the more actively traded Indian pharma names this week. The stock sits near the upper end of its recent range on the National Stock Exchange, supported by steady gains over the past six and twelve months according to Upstox data.
All news and key data on Lupin stock
For more regulatory filings, financial reports and historical price data on Lupin, the following resources provide structured overviews.
How Lupin shares performed this week
On Friday, Lupin shares traded around ?2,351.60 on the NSE, after opening at ?2,303.20 and touching an intraday high of ?2,355.80, according to Upstox’s live quote snapshot for 06/19/2026. Upstox data on Lupin notes a market capitalization of about ?1,06,421 crore.
The stock’s 52-week context on that page shows it is not far from its recent highs, with performance up 9.82% over six months and 19.09% year-on-year. This places Lupin among the better-performing mid- to large-cap Indian pharma names over the past year.
Sector comparison and peer context
Within India’s listed pharmaceutical universe, Lupin typically trades alongside peers such as Sun Pharmaceutical and Dr. Reddy’s, but with a somewhat lower price-to-earnings multiple than the top-valued names. Upstox shows Lupin on a trailing P/E around 19.9 and a dividend yield near 0.77% as of Friday. The same snapshot underscores its status as a sizeable but not mega-cap pharma stock.
This valuation places Lupin broadly in the middle of the Indian pharma pack: not as stretched as the highest-growth specialty players, but richer than some smaller generic-focused firms. Against this backdrop, the stock’s double-digit 12-month gain looks consistent with a sector that has seen renewed interest in healthcare and export-driven earnings.
The product behind the stock
Lupin generates most of its revenue from generic and branded generic medicines in therapeutic areas such as cardiovascular disease, diabetes, respiratory conditions and anti-infectives, alongside active pharmaceutical ingredients. The group has a portfolio of more than 1,000 products across global markets, according to its corporate profile. Lupin’s company overview highlights its presence in over 100 countries.
Where the stock trades today
Lupin shares (INE326A01037) trade on the National Stock Exchange of India at about ?2,351.60 as of 06/19/2026, 13:18 IST.
Key facts on Lupin stock
- Company: Lupin Ltd.
- ISIN: INE326A01037
- WKN: 572272
- Ticker: LUPIN
- Venue: NSE (India)
- Price (as of 06/19/2026, 13:18 IST): 2,351.60 INR
- Market cap: 1,06,421 crore INR (as of 06/19/2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: Nifty 50
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
